SGO Winter Meeting | Conference

Targeted Therapy, Immunotherapy Are Replacing Chemotherapy in Endometrial Cancer

February 8th 2020

Researchers and practicing physicians have done as much as possible with chemotherapy as a systemic treatment for endometrial cancers, and other modalities—alone and in combination—are likely to become standard of care in the coming years, Shannon N. Westin, MD, MPH, said during a presentation at the 2020 SGO Winter Meeting.

Expert: Frontline Maintenance With PARP Inhibition Should Be Standard in Ovarian Cancer

February 7th 2020

Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.

Patient Selection Key to Future of Immunotherapy in Endometrioid Disease

January 22nd 2019

Successful application of immunotherapy in endometrial cancer means identifying the patients with inflamed tumors who will respond to treatment and those who will not, and finding ways to treat noninflamed tumors with immunotherapy agents.

Ongoing Research to Move Needle Forward in Gynecologic Cancer Treatment

January 21st 2019

Robert Coleman, MD, highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

Dr. Leath Discusses Unmet Need in Cervical Cancer

January 20th 2019

Charles A. Leath III, MD, gyn oncologist at the University of Alabama at Birmingham, discusses the glaring unmet need in cervical cancer.

Dr. Coleman on Advances Made in Ovarian Cancer Treatment

January 20th 2019

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses advances made in the treatment of ovarian cancer.

Antiangiogenics, ADCs Still Have Roles in Ovarian Cancer Treatment

January 20th 2019

For all the positive data associated with PARP inhibitors in patients with epithelial ovarian cancer who have known BRCA mutations and despite several agents winning FDA approval over the past few years, PARP inhibitors aren’t curing patients.

Westin Highlights the Evolving Role of PARP Inhibitors in Ovarian Cancer

January 19th 2019

Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

Dr. Suarez Mora On Sequential Sampling of IP Fluid During Chemotherapy

January 19th 2019

Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.

Dr. Essel on Quantitative Computed Tomography Image Feature Analysis in Gynecologic Cancers

January 19th 2019

Kathleen G. Essel, MD, gynecologic oncology fellow at the University of Oklahoma Health Science Center with the Stephenson Cancer Center, discusses the benefits of using quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in patients with gynecologic cancers.

Dr. Lefkowits Addresses Misconceptions About Palliative Care Integration

January 19th 2019

Carolyn Lefkowits, MD, gynecologic oncologist, and palliative care doctor, at the University of Colorado, addresses common misconceptions regarding palliative care integration.

Investigators Still Seeking Options Beyond PARP Inhibitors in Ovarian Cancer

January 19th 2019

Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.

Immunotherapy Agents Could Improve Survival in Advanced Cervical Cancer

January 19th 2019

The prognosis for women with recurrent or metastatic cervical cancer after treatment failure is notoriously poor, but immunotherapy agents may offer longer survival for this population.

Dr. Kurnit on Adjuvant Chemotherapy Regimens in Mucinous Ovarian Cancer

January 19th 2019

Katherine Kurnit, MD, OBGYN oncology fellow at the University of Texas MD Anderson Cancer Center, compares the benefit of gastrointestinal-based versus gynecologic-based adjuvant chemotherapy regimens in patients with mucinous ovarian cancer.

Adjuvant GI-Based Chemo Regimens Improve Survival in Mucinous Ovarian Cancer

January 19th 2019

Results from a recent retrospective study indicate that treatment with a gastrointestinal-based adjuvant chemotherapy regimen may be more beneficial than that of a gynecologic-based one in patients with mucinous ovarian cancer.

Genomic Testing Has Impact on Treatment Decisions in Ovarian Cancer

January 18th 2019

Genomic testing to guide treatment decisions for women with ovarian cancer is in its early days. However, as more platforms become commercially available, physicians will need to understand the similarities and differences between tests.

Dr. Kalogera on Bowel Preparation Following Minimally Invasive or Open Hysterectomies

January 18th 2019

Eleftheria Kalogera, MD, MSc, instructor in Obstetrics and Gynecology, fellow in Gynecologic Oncology, in the department of Obstetrics and Gynecology, at Mayo Clinic College of Medicine, discusses the controversial topic of bowel preparation following minimally invasive or open hysterectomies.

Dr. Westin on Advances Made With PARP Inhibitors in Ovarian Cancer

January 18th 2019

Shannon N. Westin, MD, MPH, associate professor, The University of Texas MD Anderson Cancer Center, discusses advances made with PARP inhibitors in the ovarian cancer treatment paradigm.

PARP Combos May Represent Future in Frontline Maintenance Ovarian Cancer Setting

January 18th 2019

Several ongoing trials are examining combinations of PARP inhibitors and immunotherapy agents as frontline maintenance for patients with ovarian cancer.

Immunotherapy Combos on Horizon for Ovarian Cancer

February 11th 2018

Several phase III studies are exploring immunotherapy combinations with the potential to disrupt the systemic treatment paradigm for patients with ovarian cancer.